Meridian Bioscience Inc (VIVO)

15.30
NASDAQ : Health Care
Prev Close 15.30
Day Low/High 0.00 / 0.00
52 Wk Low/High 10.75 / 20.68
Avg Volume 333.50K
Exchange NASDAQ
Shares Outstanding 42.20M
Market Cap 641.48M
EPS 0.80
P/E Ratio 21.41
Div & Yield 0.50 (3.30%)

Latest News

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Meridian Bioscience, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Meridian Bioscience, Inc.

Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiative On Risks Of Lead Exposure For Pregnant Women

Kickoff panel highlights common risks and what obstetricians can do to help protect their patients

Meridian Bioscience Named Top Dividend Stock With Insider Buying and 3.38% Yield (VIVO)

In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider's view of the business, and presumably the only reason an insider would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both.

New Testing Procedure Holds Promise As A Critical Tool In The Global Effort To Eliminate Malaria

Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options

ECCMID Presentation To Demonstrate Revolutionary Breakthrough In Malaria Detection

New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria

First Week of VIVO May 19th Options Trading

Investors in Meridian Bioscience Inc. saw new options become available this week, for the May 19th expiration.

The VIVO Paradox: Analysts Bearish But Forecast 10.67% Gains

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Meridian Bioscience Inc. .

Oversold Conditions For Meridian Bioscience (VIVO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Meridian Bioscience, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against Meridian Bioscience, Inc.

Meridian Bioscience (VIVO) Passes Through 4% Yield Mark

Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Meridian Bioscience Inc. were yielding above the 4% mark based on its quarterly dividend (annualized to $0.50), with the stock changing hands as low as $12.30 on the day.

Meridian Bioscience About To Put More Money In Your Pocket (VIVO)

Looking at the universe of stocks we cover at Dividend Channel, on 2/2/17, Meridian Bioscience Inc. will trade ex-dividend, for its quarterly dividend of $0.125, payable on 2/16/17.

Top Buys by Top Brass: EVP, Pres Global Operations Baldini's $129.2K Bet on VIVO

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both.

That's Odd: Bearish VIVO Analysts See 39.06% Upside

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Meridian Bioscience Inc. .